Get the Stockscreener App
9.885
0.90%
-0.085
Evolus Inc stock is traded at $9.885, with a volume of 65,888.
It is down -0.90% in the last 24 hours and down -18.21% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$9.97
Open:
$9.98
24h Volume:
65,888
Relative Volume:
0.07
Market Cap:
$637.06M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-9.1528
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+0.71%
1M Performance:
-18.21%
6M Performance:
-24.58%
1Y Performance:
-24.06%
1-Day Range:
$9.745
$9.98
1-Week Range:
$8.75
$10.06
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.88 | 632.51M | 202.09M | -61.69M | -35.64M | -1.08 |
|
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.65 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.20 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Midday Stock Roundup: Activist Investor Targets El Pollo Loco - Orange County Business Journal
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - marketscreener.com
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus CFO Sandra Beaver resigns for new role - Investing.com
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to 16 newly hired non-executive employees - BioSpace
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Evolus Executives Sell Shares to Cover Tax Obligations - TradingView
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Voya Investment Management LLC - Defense World
Evolus, Inc. (EOLS): A Bull Case Theory - Insider Monkey
Evolus (NASDAQ:EOLS) Earns Buy Rating from Needham & Company LLC - Defense World
Evolus projects $345M-$355M revenue for 2025 with new product launches - MSN
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report - simplywall.st
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Arcus Biosciences (RCUS) - The Globe and Mail
Evolus, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
EOLS Stock: Needham Reiterates Buy Rating with $22 Target | EOLS Stock News - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Evolus Stock - Benzinga
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Yahoo Finance
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus, Inc. Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Evolus Q1 2025 results miss forecasts, stock rises - Investing.com Nigeria
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.28%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):